Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous expanded CD34+ stem cell infusion for chronic liver insufficiency
2005-001222-83Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Aug 2005
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous expanded CD34+ stem cells in Chronic liver insufficiency (CLD) and Cirrhosis, sponsored by Imperial College London. Primary endpoints: Safety of ascending doses of autologous adult stem cells and Maximum tolerated dose. Started Aug 2005; status: completed.
02
Drugs
autologous expanded CD34+ stem cells
03
Conditions
Chronic liver insufficiency (CLD)Cirrhosis
Beyond the preview
Go deeper on 2005-001222-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001222-83.